Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Published Date: 14 Oct 2026

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Read Full News

Latest News

Optimizing IBD Treatment and Sequencing, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents

Same PFAS Metabolites Tied to Maternal IBD Linked to Child Calprotectin Elizabeth Spencer, MD, MS

Elizabeth Spencer, MD, discusses new data from 3 birth cohorts linking PFAS metabolites tied to maternal IBD to elevated calprotectin in children.

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

5 Gastroenterology Headlines You Missed in September 2026

5 Gastroenterology Headlines You Missed in September 2026

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

Todays Updates

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

Latest News

Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents

Elizabeth Spencer, MD, discusses new data from 3 birth cohorts linking PFAS metabolites tied to maternal IBD to elevated calprotectin in children.

A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

5 Gastroenterology Headlines You Missed in September 2026

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

News All Time

4 Gastroenterology Headlines You Missed in June 2026 Abigail Brooks, MA

Catch up on phase 3 data for tulisokibart and obefazimod, expert perspective on linaclotide's expanded FDA approval, and more.

Q2 2026 Recap: Gastroenterology News & Updates Abigail Brooks, MA

Catch up on Q2 GI headlines you may have missed, including an expanded FDA approval for linaclotide, a submission for risankizumab SC induction in Crohn’s, and more.

SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study Abigail Brooks, MA

Freenome reported updated SimpleScreen CRC results showing 80.4% colorectal cancer sensitivity and 90% specificity.

First Half 2026 Recap: Gastroenterology Alex Hillenbrand

Review the biggest gastroenterology news from the first half of 2026, including FDA updates, IBD advances, and key clinical trials.

"Forever Chemicals" Are in Cord Blood And Tied to Gut Inflammation in Kids Elizabeth Spencer, MD, MS

PFAS found in cord blood linked to childhood gut inflammation and IBD risk; Elizabeth Spencer, MD, explains what it means for patients.

How FDA Approval of SimpleScreen CRC Could Expand Colorectal Cancer Screening With Mark Fendrick, MD Mark Fendrick, MD

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged 45 years and older.

FDA Approves Freenome Blood Test for Colorectal Cancer Screening Alex Hillenbrand

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged ≥45 years.

TL1A Antibody Duvakitug Boosts Clinical Remission in UC, Response in CD Abigail Brooks, MA

Newly published phase 2b RELIEVE UCCD data show strong 14-week results for duvakitug in ulcerative colitis and Crohn disease.

ABTECT Part 2 Data: Obefazimod Sustains Remission in UC Remo Panaccione, MD, FRCPC

Remo Panaccione, MD, discusses ABTECT Part 2 data: about 37% of prior non-responders achieved remission, with no new safety signals.

How a Physician With Crohn's Disease Approaches IBD Care Jordan Axelrad, MD, MPH

Jordan E. Axelrad, MD, MPH, on selecting first-line IBD therapy, treat-to-target monitoring, and how living with Crohn's shapes patient care.

Metabolic Dysfunction May Explain Sugar-Sweetened Beverage–Gastric Cancer Link, With Andrew Chan, MD, MPH Andrew Chan, MD, MPH

New findings link sugar-sweetened beverages, but not artificial sweeteners, to increased gastric cancer risk, possibly tied to metabolic dysfunction.

Sugar-Sweetened Beverages Associated With Increased Gastric Cancer Risk, With Andrew Chan, MD, MPH Andrew Chan, MD, MPH

2-decade cohort study of 112,284 participants finds sugar-sweetened beverage intake linked to gastric cancer risk, with no link for artificial sweeteners.

TEV '408 Meets Primary Endpoint in Celiac Trial Alex Hillenbrand

The phase 2a study found TEV '408 significantly reduced intestinal damage and inflammation versus placebo at week 8

Comprehensive Disease Control Starts With Asking, With David T. Rubin, MD

Comprehensive Disease Control Starts With Asking, With David T. Rubin, MD

6 Gastroenterology Headlines You Missed in August 2026 Alex Hillenbrand

Gastroenterology in August 2026: RAS inhibitor approval for pancreatic cancer, ABTECT UC data, CRC screening mortality, and GI cancer risk.

43% Lower Mortality Seen in Colorectal Screening Participants Johannes Blom, MD, PhD

Karolinska Institute's Johannes Blom, MD, PhD, explains why colorectal cancer screening's real-world mortality benefit has been underestimated.

Recommended News For You

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace

NEJM: Fluorescent guide can aid in the detection of tumors that are still present after breast cancer surgery.

Should the UK introduce targeted prostate cancer screening? The case for and against

Ranking of the Best US Hospitals for Psychiatric Care.

Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer

Reversing the toxic relationship with high doses of chemotherapy in oncology.

Laser Therapy Shows Promise for Brain Tumors

Recommended Articles For You

Modern Approaches to Detecting Residual Disease: Clinical Utility and Future Trends 

Case Study: The Role of JAK Inhibitors in Myeloproliferative Disorders 

Understanding Fibrosarcoma: What You Need to Know  

The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Taking Charge of Your Cancer Journey.

2.

Oleanolic acid from grapes may increase chemotherapy effectiveness

3.

Cancer deaths expected to rise to over 18 million in 2050, nearly 75% more than in 2024

4.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

5.

Cancerous breast tissue glows in new AI-enhanced MRI images

1.

Spatial Tumor Mapping for Individualized Cancer Therapy

2.

Management of Relapsed Synovial Sarcoma: Current Treatment Strategies and Emerging Therapies

3.

Metabolic Plasticity in the Progression of Solid Tumors

4.

Everything You Need to Know About Normal Potassium Levels 

5.

Prognosis of Hematologic Recovery After Severe Cytopenia

1.

International Conference on Oncology, Cardiology and Critical Care Policy

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Cancer Nursing and Hematology Support

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

2.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

3.

Efficient Management of First line ALK-rearranged NSCLC - Part III

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

5.

Recognizing Symptoms That May Require Cancer Evaluation

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot